ChemoCentryx is a biopharmaceutical company developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of our drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. The Company's drug candidates are small molecules, which are orally administered, offering significant quality of life benefits, since patients swallow a capsule or pill instead of having to visit a clinic for an infusion or undergo an injection.

Type
Public
HQ
Mountain View, US
Founded
1997
Size (employees)
62 (est)
ChemoCentryx was founded in 1997 and is headquartered in Mountain View, US
Report incorrect company information

Key People/Management at ChemoCentryx

Thomas J. Schall

Thomas J. Schall

President, Chief Executive Officer and Chairman of the Board
Markus J. Cappel

Markus J. Cappel

Chief Business Officer and Treasurer
Show more

ChemoCentryx Office Locations

ChemoCentryx has an office in Mountain View
Mountain View, US (HQ)
850 Maude Avenue
Show all (1)
Report incorrect company information

ChemoCentryx Financials and Metrics

ChemoCentryx Revenue

ChemoCentryx's revenue was reported to be $82.50 m in FY, 2017
USD

Net income (Q2, 2018)

(16.3 m)

EBIT (Q2, 2018)

(17.3 m)

Market capitalization (16-Aug-2018)

551.6 m

Closing stock price (16-Aug-2018)

11

Cash (30-Jun-2018)

68.8 m

EV

497.6 m
ChemoCentryx's current market capitalization is $551.6 m.
Annual
USDFY, 2016FY, 2017

Revenue

11.9 m82.5 m

General and administrative expense

14.7 m16.5 m

R&D expense

37.9 m49.5 m

Operating expense total

52.7 m66 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

2.8 m4.3 m8.2 m9 m9.5 m

General and administrative expense

3.4 m3.5 m3.7 m3.6 m3.8 m4.1 m3.9 m3.2 m4.6 m4.7 m9.4 m

R&D expense

9 m7.5 m8.4 m8.6 m7.9 m11.2 m9.1 m8.4 m10 m14.7 m32.5 m

Operating expense total

12.4 m11.1 m12.1 m12.2 m11.7 m15.3 m12.9 m11.6 m14.5 m15.9 m19.4 m41.9 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

10.3 m16.1 m12.8 m12 m40 m

Accounts Receivable

30.2 m51.1 m

Inventories

596 k972 k757 k722 k

Current Assets

134.3 m74.3 m72 m148.7 m179.8 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

13.1 m20.9 m25.4 m11.6 m14.6 m13.4 m21.9 m13.9 m19 m18 m30.6 m68.8 m

Accounts Receivable

175 k120 k30.2 m530 k1.7 m164 k

Inventories

1.3 m

Current Assets

100.8 m86.1 m76.1 m71.4 m74.2 m65.2 m127 m122.7 m119.9 m122.4 m149.8 m184.9 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(38.7 m)(46.9 m)(47.3 m)(40 m)17.9 m

Depreciation and Amortization

576 k543 k477 k348 k418 k

Inventories

Accounts Payable

159 k(161 k)(73 k)(4 k)729 k
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(12.3 m)(10.9 m)(12 m)(12.1 m)(11.6 m)(15.2 m)(10 m)(7.1 m)(6 m)(6.6 m)(9.4 m)(16.3 m)

Depreciation and Amortization

111 k227 k

Inventories

1.3 m

Accounts Payable

690 k1 m809 k1 m615 k1.3 m513 k840 k819 k1.4 m(951 k)(378 k)
USDY, 2018

EV/EBIT

-28.7 x

EV/CFO

10.1 x

Financial Leverage

7.1 x
Show all financial metrics
Report incorrect company information

ChemoCentryx Company Life and Culture

Report incorrect company information